*Patient verbatim and profile comes from hypothetical patient for illustrative purpose only
**Guidelines developed by European Academy of Allergy and Clinical Immunology, Global Allergy and Asthma European Network, European Dermatology Forum and the World Allergy Organization.
***Xolair® is also available as a lyophilized formulation
†Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients
‡Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo.
References: 1. Zerbier T et al. Eur J Allergy Clin Immunol 2014;69:868–887. 2. Xolair® Summary of Product of Characteristics 2016. 3. Maurer M, et al. N Engl J Med 2013;368:924-935.